Pharmacological aspects of the combined use of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and gamma-hydroxybutyric acid (GHB): a review of the literature

References

• Club Health. The 2nd international conference on night-life substance use and related health issues. 2002, 24 – 27 March 2002, Fiera District, Rimini, Italy
   Google Scholar
• Teter C J, Guthrie S K. A comprehensive review of MDMA and GHB: two common club drugs. Pharmacotherapy 2001; 21: 1486–1513
   PubMed Web of Science ®Google Scholar
• Johnston L D, O'Malley P M, Bachman J G. ‘Ecstasy’ use rises sharply among teens in 2000 2003, Accessed 1 February. Available at: www.monitoringthefuture.org
   Google Scholar
• EMCDDA. The European Monitoring Centre for Drugs and Drug Addiction. Annual report on the state of the drugs problem in the European Union. EMCDDA, Lisboa 2002
   Google Scholar
• Bravo G L. What does MDMA feel like?. Ecstasy: the complete guide, J Holland. Park Street Press, Rochester, Vermont 2001; 21–28
   Google Scholar
• Vollenweider F X, Gamma A, Liechti M, Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA (‘ecstasy’) in MDMA-naive healthy volunteers. Neuropsychopharmacology 1998; 19: 241–251
   PubMed Web of Science ®Google Scholar
• Cohen R S. Subjective reports on the effects of the MDMA (‘ecstasy’) experience in humans. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 1137–1145
   PubMed Web of Science ®Google Scholar
• Siegel R K. MDMA. Nonmedical use and intoxication. J Psychoact Drugs 1986; 18: 349–354
   PubMed Web of Science ®Google Scholar
• Mas M, Farre M, de la Torre R, Roset P N, et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 1999; 290: 136–145
   PubMed Web of Science ®Google Scholar
• Nichols D E. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoact Drugs 1986; 18: 305–313
   PubMed Web of Science ®Google Scholar
• Gouzoulis-Mayfrank E, Hermle L, Kovar K A, Sass H. [Entactogenic drugs ‘ecstasy’ (MDMA), ‘eve’ (MDE) and other ring-substituted methamphetamine derivatives. A new class of substances among illegal designer drugs?]. Nervenarzt 1996; 67: 369–380
   PubMed Web of Science ®Google Scholar
• Velea D, Hautefeuille M, Vazeille G, Lantran-Davoux C. Nouvelles drogues synthetiques empathogenes [New synthesis empathogenic agents]. Encephale 1999; 25: 508–514
   PubMed Web of Science ®Google Scholar
• Dean W, Morgenthaler J, Fowkes S WM. GHB: the natural mood enhancer. Smart Publications, Petaluma 1997
   Google Scholar
• Doyon S. The many faces of ecstasy. Curr Opin Pediatr 2001; 13: 170–176
   PubMed Web of Science ®Google Scholar
• Haasen C. Patterns of consumption. Eur Addict Res 2001; 7: 1
   PubMed Web of Science ®Google Scholar
• Tossmann P, Boldt S, Tensil M D. The use of drugs within the techno party scene in European metropolitan cities. Eur Addict Res 2001; 7: 2–23
   PubMed Web of Science ®Google Scholar
• Winstock A R, Griffiths P, Stewart D. Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend 2001; 64: 9–17
   PubMed Web of Science ®Google Scholar
• Cottler L B, Womack S B. Ecstasy abuse and dependence among adolescents and young adults: applicability and reliability of DSM-IV criteria. Hum Psychopharmacol Clin Exp 2001; 16: 627–633
   PubMed Web of Science ®Google Scholar
• Miotto K, Darakjian J, Basch J, Murray S, Zogg J, Rawson R. Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal. Am J Addict 2001; 10: 232–241
   PubMed Web of Science ®Google Scholar
• Korf D J, Nabben T, Leenders F, Benschop A. GHB: tussen extase en narcose. Rozenberg Publishers, Amsterdam 2002
   Google Scholar
• Drug Abuse Warning Network. The DAWN report, Available at: http://www.samsha.gov/oms/dawn.hm. Accessed 6 April 2001
   Google Scholar
• Nabben T, Korf D J. De combi-roes: gecombineerd gebruik van alcohol met cannabis, cocaine, XTC en amfetamine. Rozenberg Publishers, Amsterdam 2000
   Google Scholar
• Maitre M. The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. Prog Neurobiol 1997; 51: 337–361
   PubMed Web of Science ®Google Scholar
• Simantov R. Multiple molecular and neuropharmacological effects of MDMA (Ecstasy). Life Sci 2004; 74: 803–814
   PubMed Web of Science ®Google Scholar
• Nava F, Carta G, Bortolato M, Gessa G L. gamma-Hydroxybutyric acid and baclofen decrease extracellular acetylcholine levels in the hippocampus via GABA(B) receptors. Eur J Pharmacol 2001; 430: 261–263
   PubMed Web of Science ®Google Scholar
• Schmidt-Mutter C, Gobaille S, Muller C, Maitre M. Prodynorphin and proenkephalin mRNAs are increased in rat brain after acute and chronic administration of gamma-hydroxybutyrate. Neurosci Lett 1999; 262: 65–68
   PubMed Web of Science ®Google Scholar
• Malberg J E, Bonson K R. How MDMA works in the brain. Ecstasy: the complete guide, J Holland. Park Street Press, Rochester, Vermont 2001; 29–38
   Google Scholar
• Okun M S, Boothby L A, Bartfield R B, Doering P L. GHB: an important pharmacologic and clinical update. J Pharm Pharm Sci 2001; 4: 167–175
   PubMed Web of Science ®Google Scholar
• Cole J C, Sumnall H R. The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci Biobehav Rev 2003; 27: 199–217
   PubMed Web of Science ®Google Scholar
• Green A R, Mechan A O, Elliott J M, O'Shea E, Colado M I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’). Pharmacol Rev 2003; 55: 463–508
   PubMed Web of Science ®Google Scholar
• Colado M I, O'Shea E, Green A R. Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function. Psychopharmacology (Berl) 2004; 173: 249–263
   PubMed Web of Science ®Google Scholar
• Roth R H. Formation and regional distribution of gamma-hydroxybutyric acid in mammalian brain. Biochem Pharmacol 1970; 19: 3013–3019
   PubMed Web of Science ®Google Scholar
• Doherty J D, Hattox S E, Snead O C, Roth R H. Identification of endogenous gamma-hydroxybutyrate in human and bovine brain and its regional distribution in human, guinea pig and rhesus monkey brain. J Pharmacol Exp Ther 1978; 207: 130–139
   PubMed Web of Science ®Google Scholar
• Cash C D. Gamma-hydroxybutyrate: an overview of the pros and cons for it being a neurotransmitter and/or a useful therapeutic agent. Neurosci Biobehav Rev 1994; 18: 291–304
   PubMed Web of Science ®Google Scholar
• Laborit H. Sodium 4-Hydroxybutyrate. Int J Neuropharmacol 1964; 32: 433–451
   Google Scholar
• Bernasconi R, Mathivet P, Bischoff S, Marescaux C. Gamma-hydroxybutyric acid: an endogenous neuromodulator with abuse potential?. Trends Pharmacol Sci 1999; 20: 135–141
   PubMed Web of Science ®Google Scholar
• Galloway G P, Frederick S L, Staggers F -EJ, Gonzales M, Stalcup S A, Smith D E. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction 1997; 92: 89–96
   PubMed Web of Science ®Google Scholar
• Wong C G, Gibson K M, Snead O C, III. From the street to the brain: neurobiology of the recreational drug gamma-hydroxybutyric acid. Trends Pharmacol Sci 2004; 25: 29–34
   PubMed Web of Science ®Google Scholar
• Aghajanian G K, Marek G J. Serotonin and hallucinogens. Neuropsychopharmacology 1999; 21(Suppl 2)S16–S23
   PubMed Web of Science ®Google Scholar
• Oberlender R, Nichols D E. (+)-N-methyl-1-(1,3-benzodioxol-5-yl)- 2-butanamine as a discriminative stimulus in studies of 3,4-methylenedioxy-methamphetamine-like behavioural activity. J Pharmacol Exp Ther 1990; 255: 1098–1106
   PubMed Web of Science ®Google Scholar
• Green A R, Cross A J, Goodwin G M. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or ‘Ecstasy’). Psychopharmacology (Berl) 1995; 119: 247–260
   PubMed Web of Science ®Google Scholar
• Huether G, Zhou D, Ruther E. Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) and its congeners. J Neural Transm 1997; 104: 771–794
   PubMed Web of Science ®Google Scholar
• Partilla J S, Dersch C M, Yu H, Rice K C, Rothman R B. Neurochemical neutralization of amphetamine-type stimulants in rat brain by the indatraline analog (–)-HY038. Brain Res Bull 2000; 53: 821–826
   PubMed Web of Science ®Google Scholar
• Gu X F, Azmitia E C. Integrative transporter-mediated release from cytoplasmic and vesicular 5-hydroxytryptamine stores in cultured neurons. Eur J Pharmacol 1993; 235: 51–57
   PubMed Web of Science ®Google Scholar
• Brodkin J, Malyala A, Nash J F. Effect of acute monoamine depletion on 3,4- methylenedioxymethamphetamine-induced neurotoxicity. Pharmacol Biochem Behav 1993; 45: 647–653
   PubMed Web of Science ®Google Scholar
• Schmidt C J, Levin J A, Lovenberg W. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem Pharmacol 1987; 36: 747–755
   PubMed Web of Science ®Google Scholar
• Hekmatpanah C R, Peroutka S J. 5-hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methylenedioxymethamphetamine and related agents. Eur J Pharmacol 1990; 177: 95–98
   PubMed Web of Science ®Google Scholar
• White S R, Obradovic T, Imel K M, Wheaton M J. The effects of methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) on monoaminergic neurotransmission in the central nervous system. Prog Neurobiol 1996; 49: 455–479
   PubMed Web of Science ®Google Scholar
• Gudelsky G A, Nash J F. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem 1996; 66: 243–249
   PubMed Web of Science ®Google Scholar
• Koch S, Galloway M P. MDMA induced dopamine release in vivo: role of endogenous serotonin. J Neural Transm 1997; 104: 135–146
   PubMed Web of Science ®Google Scholar
• Fletcher P J, Korth K M, Robinson S R, Baker G B. Multiple 5-HT receptors are involved in the effects of acute MDMA treatment: studies on locomotor activity and responding for conditioned reinforcement. Psychopharmacology (Berl) 2002; 162: 282–291
   PubMed Web of Science ®Google Scholar
• Bengel D, Murphy D L, Andrews A M, et al. Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine (‘Ecstasy’) in serotonin transporter-deficient mice. Mol Pharmacol 1998; 53: 649–655
   PubMed Web of Science ®Google Scholar
• Battaglia G, Brooks B P, Kulsakdinun C, de Souza E B. Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 1988; 149: 159–163
   PubMed Web of Science ®Google Scholar
• Stone D M, Stahl D C, Hanson G R, Gibb J W. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4- methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol 1986; 128: 41–48
   PubMed Web of Science ®Google Scholar
• Leonardi E T, Azmitia E C. MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology 1994; 10: 231–238
   Google Scholar
• Callaway C W, Wing L L, Geyer M A. Serotonin release contributes to the locomotor stimulant effects of 3,4- methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther 1990; 254: 456–464
   PubMed Web of Science ®Google Scholar
• Rempel N L, Callaway C W, Geyer M A. Serotonin1B receptor activation mimics behavioural effects of presynaptic serotonin release. Neuropsychopharmacology 1993; 8: 201–211
   PubMed Web of Science ®Google Scholar
• Nash J F, Jr, Meltzer H Y, Gudelsky G A. Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther 1988; 245: 873–879
   Google Scholar
• Liechti M E, Baumann C, Gamma A, Vollenweider F X. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 2000; 22: 513–521
   PubMed Web of Science ®Google Scholar
• Liechti M E, Saur M R, Gamma A, Hell D, Vollenweider F X. Psychological and physiological effects of MDMA (‘Ecstasy’) after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology 2000; 23: 396–404
   PubMed Web of Science ®Google Scholar
• Liechti M E, Vollenweider F X. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol Clin Exp 2001; 16: 589–598
   PubMed Web of Science ®Google Scholar
• Liechti M E, Geyer M A, Hell D, Vollenweider F X. Effects of MDMA (Ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin. Neuropsychopharmacology 2001; 24: 240–252
   PubMed Web of Science ®Google Scholar
• Liechti M E, Vollenweider F X. The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine (‘Ecstasy’) in healthy volunteers. J Psychopharmacol 2000; 14: 269–274
   PubMed Web of Science ®Google Scholar
• Spano P F, Przegalinski E. Stimulation of serotonin synthesis by anesthetic and non-anesthetic doses of gamma-hydroxybutyrate. Pharmacol Res Commun 1973; 5: 55–69
   Google Scholar
• Waldmeier P C, Fehr B. Effects of baclofen and gamma-hydroxybutyrate on rat striatal and mesolimbic 5-HT metabolism. Eur J Pharmacol 1978; 49: 177–184
   PubMed Web of Science ®Google Scholar
• Hedner T, Lundborg P. Effect of gammahydroxybutyric acid on serotonin synthesis, concentration and metabolism in the developing rat brain. J Neural Transm 1983; 57: 39–48
   PubMed Web of Science ®Google Scholar
• Miguez I, Aldegunde M, Duran R, Veira J A. Effect of low doses of gamma-hydroxybutyric acid on serotonin, noradrenaline, and dopamine concentrations in rat brain areas. Neurochem Res 1988; 13: 531–533
   PubMed Web of Science ®Google Scholar
• Gobaille S, Schleef C, Hechler V, Viry S, Aunis D, Maitre M. Gamma-hydroxybutyrate increases tryptophan availability and potentiates serotonin turnover in rat brain. Life Sci 2002; 70: 2101–12112
   PubMed Web of Science ®Google Scholar
• Malison R T, Best S E, Wallace E A, et al. Euphorigenic doses of cocaine reduce [123I]beta-CIT SPECT measures of dopamine transporter availability in human cocaine addicts. Psychopharmacology (Berl) 1995; 122: 358–362
   PubMed Web of Science ®Google Scholar
• Volkow N D, Wang G J, Fischman M W, et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 1997; 386: 827–830
   PubMed Web of Science ®Google Scholar
• Wise S P, Murray E A, Gerfen C R. The frontal cortex – basal ganglia system in primates. Crit Rev Neurobiol 1996; 10: 317–356
   PubMed Web of Science ®Google Scholar
• Kuhar M J, Ritz M C, Boja J W. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 1991; 14: 299–302
   PubMed Web of Science ®Google Scholar
• Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988; 85: 5274–5278
   PubMed Web of Science ®Google Scholar
• Bilsky E J, Montegut M J, Nichols M L, Reid L D. CGS 10746B, a novel dopamine release inhibitor, blocks the establishment of cocaine and MDMA conditioned place preferences. Pharmacol Biochem Behav 1998; 59: 215–220
   PubMed Web of Science ®Google Scholar
• Yamamoto B K, Nash J F, Gudelsky G A. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J Pharmacol Exp Ther 1995; 273: 1063–1070
   PubMed Web of Science ®Google Scholar
• Sasaki-Adams D M, Kelley A E. Serotonin-dopamine interactions in the control of conditioned reinforcement and motor behaviour. Neuropsychopharmacology 2001; 25: 440–452
   PubMed Web of Science ®Google Scholar
• Gough B, Imam S Z, Blough B, Slikker W, Jr, Ali S F. Comparative effects of substituted amphetamines (PMA, MDMA, and METH) on monoamines in rat caudate: a microdialysis study. Ann NY Acad Sci 2002; 965: 410–420
   PubMed Web of Science ®Google Scholar
• Kalivas P W, Duffy P, White S R. MDMA elicits behavioural and neurochemical sensitization in rats. Neuropsychopharmacology 1998; 18: 469–479
   PubMed Web of Science ®Google Scholar
• Shankaran M, Gudelsky G A. Effect of 3,4-methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin. Pharmacol Biochem Behav 1998; 61: 361–366
   PubMed Web of Science ®Google Scholar
• Gough B, Ali S F, Slikker W, Jr, Holson R R. Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate. Pharmacol Biochem Behav 1991; 39: 619–623
   PubMed Web of Science ®Google Scholar
• Schmidt C J, Sullivan C K, Fadayel G M. Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J Neurochem 1994; 62: 1382–1389
   PubMed Web of Science ®Google Scholar
• Nash J F, Brodkin J. Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced dopamine release: effect of dopamine uptake inhibitors. J Pharmacol Exp Ther 1991; 259: 820–825
   PubMed Web of Science ®Google Scholar
• Pan H S, Wang R Y. MDMA: further evidence that its action in the medial prefrontal cortex is mediated by the serotonergic system. Brain Res 1991; 539: 332–336
   PubMed Web of Science ®Google Scholar
• Johnson M P, Hoffman A J, Nichols D E. Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur J Pharmacol 1986; 132: 269–276
   PubMed Web of Science ®Google Scholar
• Yamamoto B K, Spanos L J. The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur J Pharmacol 1988; 148: 195–203
   PubMed Web of Science ®Google Scholar
• White S R, Duffy P, Kalivas P W. Methylenedioxymethamphetamine depresses glutamate-evoked neuronal firing and increases extracellular levels of dopamine and serotonin in the nucleus accumbens in vivo. Neuroscience 1994; 62: 41–50
   PubMed Web of Science ®Google Scholar
• Porrino L J, Ritz M C, Goodman N L, Sharpe L G, Kuhar M J, Goldberg S R. Differential effects of the pharmacological manipulation of serotonin systems on cocaine and amphetamine self-administration in rats. Life Sci 1989; 45: 1529–1535
   PubMed Web of Science ®Google Scholar
• Geyer M A, Callaway C W. Behavioural pharmacology of ring-substituted amphetamine analogs. Amphetamine and its analogs: psychopharmacology, toxicology, and abuse, A K Cho, S Segal. Academic Press, New York 1994; 177–208
   Google Scholar
• Dafters R I, Lynch E. Persistent loss of thermoregulation in the rat induced by 3,4-methylenedioxymethamphetamine (MDMA or ‘Ecstasy’) but not by fenfluramine. Psychopharmacology (Berl) 1998; 138: 207–212
   PubMed Web of Science ®Google Scholar
• Gordon C J, Watkinson W P, O'Callaghan J P, Miller D B. Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat. Pharmacol Biochem Behav 1991; 38: 339–344
   PubMed Web of Science ®Google Scholar
• Glennon R A, Yousif M, Patrick G. Stimulus properties of 1-(3,4-methylenedioxyphenyl)- 2-aminopropane (MDA) analogs. Pharmacol Biochem Behav 1988; 29: 443–449
   PubMed Web of Science ®Google Scholar
• Hegadoren K M, Martin-Iverson M T, Baker G B. Comparative behavioural and neurochemical studies with a psychomotor stimulant, an hallucinogen and 3,4-methylenedioxy analogues of amphetamine. Psychopharmacology (Berl) 1995; 118: 295–304
   PubMed Web of Science ®Google Scholar
• Gold L H, Geyer M A, Koob G F. Psychostimulant properties of MDMA. NIDA Res Monogr 1989; 95: 345–346
   PubMedGoogle Scholar
• Martinez-Price D L, Krebs-Thomson K, Geyer M A. Behavioural psychopharmacology of MDMA and MDMA-like drugs: a review of human and animal studies. Addict Res Theory 2002; 10: 43–67
   Web of Science ®Google Scholar
• Bankson M G, Cunningham K A. 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions. J Pharmacol Exp Ther 2001; 297: 846–852
   PubMed Web of Science ®Google Scholar
• Liechti M E, Vollenweider F X. Acute psychological and physiological effects of MDMA (‘Ecstasy’) after haloperidol pretreatment in healthy humans. Eur Neuropsychopharmacol 2000; 10: 289–295
   PubMed Web of Science ®Google Scholar
• Howard S G, Banerjee P K. Regulation of central dopamine by y-hydroxybutyrate. Gamma-hydroxybutyrate, G Tunnicliff, C D Cash. Taylor & Francis, London 2002; 111–119
   Google Scholar
• Nissbrandt H, Engberg G. The GABAB-receptor antagonist, CGP 35348, antagonises gamma-hydroxybutyrate- and baclofen-induced alterations in locomotor activity and forebrain dopamine levels in mice. J Neural Transm 1996; 103: 1255–1263
   PubMed Web of Science ®Google Scholar
• Carai M A, Colombo G, Reali R, et al. Central effects of 1,4-butanediol are mediated by GABA(B) receptors via its conversion into gamma-hydroxybutyric acid. Eur J Pharmacol 2002; 441: 157–163
   PubMed Web of Science ®Google Scholar
• Pontieri F E, Tanda G, Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the ‘shell’ as compared with the ‘core’ of the rat nucleus accumbens. Proc Natl Acad Sci USA 1995; 92: 12304–12308
   PubMed Web of Science ®Google Scholar
• Koob G F, Sanna P P, Bloom F E. Neuroscience of addiction. Neuron 1998; 21: 467–476
   PubMed Web of Science ®Google Scholar
• Robbins T W, Everitt B J. Drug addiction: bad habits add up. Nature 1999; 398: 567–570
   PubMed Web of Science ®Google Scholar
• Ritz M C, Kuhar M J. Relationship between self-administration of amphetamine and monoamine receptors in brain: comparison with cocaine. J Pharmacol Exp Ther 1989; 248: 1010–1017
   PubMed Web of Science ®Google Scholar
• Chen N H, Reith M E. Autoregulation and monoamine interactions in the ventral tegmental area in the absence and presence of cocaine: a microdialysis study in freely moving rats. J Pharmacol Exp Ther 1994; 271: 1597–1610
   PubMed Web of Science ®Google Scholar
• Chen N H, Reith M E. Effects of locally applied cocaine, lidocaine, and various uptake blockers on monoamine transmission in the ventral tegmental area of freely moving rats: a microdialysis study on monoamine interrelationships. J Neurochem 1994; 63: 1701–1713
   PubMed Web of Science ®Google Scholar
• Florin S M, Kuczenski R, Segal D S. Regional extracellular noradrenaline responses to amphetamine and cocaine and effects of clonidine pretreatment. Brain Res 1994; 654: 53–62
   PubMed Web of Science ®Google Scholar
• Florin S M, Kuczenski R, Segal D S. Effects of reserpine on extracellular caudate dopamine and hippocampus noradrenaline responses to amphetamine and cocaine: mechanistic and behavioural considerations. J Pharmacol Exp Ther 1995; 274: 231–241
   PubMed Web of Science ®Google Scholar
• Wang Y M, Xu F, Gainetdinov R R, Caron M G. Genetic approaches to studying noradrenaline function: knockout of the mouse noradrenaline transporter gene. Biol Psychiatry 1999; 46: 1124–1130
   PubMed Web of Science ®Google Scholar
• Giros B, Wang Y M, Suter S, McLeskey S B, Pifl C, Caron M G. Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-noradrenaline transporters. J Biol Chem 1994; 269: 15985–15988
   PubMed Web of Science ®Google Scholar
• Pacholczyk T, Blakely R D, Amara S G. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenalinee transporter. Nature 1991; 350: 350–354
   PubMed Web of Science ®Google Scholar
• Villemagne V L, Wong D F, Yokoi F, et al. GBR12909 attenuates amphetamine-induced striatal dopamine release as measured by [(11)C]raclopride continuous infusion PET scans. Synapse 1999; 33: 268–273
   PubMed Web of Science ®Google Scholar
• Rothman R B, Baumann M H, Dersch C M, et al. Amphetamine-type central nervous system stimulants release noradrenaline more potently than they release dopamine and serotonin. Synapse 2001; 39: 32–41
   PubMed Web of Science ®Google Scholar
• Fitzgerald J L, Reid J J. Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices. Eur J Pharmacol 1990; 191: 217–220
   PubMed Web of Science ®Google Scholar
• Lavelle A, Honner V, Docherty J R. Investigation of the prejunctional alpha2-adrenoceptor mediated actions of MDMA in rat atrium and vas deferens. Br J Pharmacol 1999; 128: 975–980
   PubMed Web of Science ®Google Scholar
• Lester S J, Baggott M, Welm S, et al. Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. Ann Intern Med 2000; 133: 969–973
   PubMed Web of Science ®Google Scholar
• Steele T D, Nichols D E, Yim G K. Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain. Biochem Pharmacol 1987; 36: 2297–2303
   PubMed Web of Science ®Google Scholar
• Griffiths R R, Bigelow G, Liebson I. Human drug self-administration: double-blind comparison of pentobarbital, diazepam, chlorpromazine and placebo. J Pharmacol Exp Ther 1979; 210: 301–310
   PubMed Web of Science ®Google Scholar
• Brauer L H, de Wit H. Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers. Biol Psychiatry 1996; 39: 26–32
   PubMed Web of Science ®Google Scholar
• Chait L D. Reinforcing and subjective effects of methylphenidate in humans. Behav Pharmacol 1994; 5: 281–288
   PubMed Web of Science ®Google Scholar
• Vargiu L, Crabai F, Camba R, Gessa G L. [Effect of gamma-butyrolactone on the cerebral content of monamine]. Boll Soc Ital Biol Sper 1966; 42: 1633–1634
   PubMedGoogle Scholar
• Gessa G L, Vargiu L, Crabai F, Boero G C, Caboni F, Camba R. Selective increase of brain dopamine induced by gamma hydroxybutyrate. Life Sci 1966; 5: 1921–1930
   Google Scholar
• Hechler V, Gobaille S, Bourguignon J J, Maitre M. Extracellular events induced by gamma-hydroxybutyrate in striatum: a microdialysis study. J Neurochem 1991; 56: 938–944
   PubMed Web of Science ®Google Scholar
• Kaufman E E, Porrino L J, Nelson T. Pyretic action of low doses of gamma-hydroxybutyrate in rats. Biochem Pharmacol 1990; 40: 2637–2640
   PubMed Web of Science ®Google Scholar
• Hernandez-Lopez C, Farre M, Roset P N, et al. 3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. J Pharmacol Exp Ther 2002; 300: 236–244
   PubMed Web of Science ®Google Scholar